The datasets analyzed in this study are available at <https://figshare.com/articles/Untitled_Item/9337469>. All the scripts required to run the proposed pipelines, are available at <https://github.com/Moumiiiiii/cell-differentiation-trees>. The ChIP-Seq histone modification data are available at ENCODE database (downloaded from <http://genome.ucsc.edu/cgi-bin/hgFileUi?db=hg19&g=wgEncodeUwHistone>) and CISTROME DB (<http://cistrome.org/db/#/>).

Introduction {#sec001}
============

Environmental Enteric dysfunction (EED) is a subclinical inflammatory disease of the small intestine characterized histologically by blunted villi, elongated crypts and increased lymphocytic infiltration of the lamina propria \[[@pone.0221095.ref001], [@pone.0221095.ref002]\]. These histological changes are associated with subsequent malabsorption, impaired cognitive development \[[@pone.0221095.ref003], [@pone.0221095.ref004]\], reduced responsiveness to nutritional intervention \[[@pone.0221095.ref005]\], and reduced immunogenicity of oral vaccine \[[@pone.0221095.ref006], [@pone.0221095.ref007]\] in apparently healthy children \[[@pone.0221095.ref008], [@pone.0221095.ref009]\]. The main impediment in diagnosis of EED is examination of upper bowel mucosa, which is impractical for a high proportion of children failing nutritional intervention \[[@pone.0221095.ref010]\]. The role of enteropathogens are well documented in studies such as Etiology, Risk Factors and Interactions of Enteric Infection and Malnutrition and the Consequences for Child Health and Development (MAL-ED) and Global Enteric Multicenter Study (GEMS) \[[@pone.0221095.ref011], [@pone.0221095.ref012]\]. However, asymptomatic enteropathogen carriage in children with EED has not been studied in detail with growth faltering and change in EED biomarkers. The knowledge of gut pathobiome in apparently healthy children may be associated with the causal pathway of EED, which is a multifactorial disease process accompanied by repeated exposure to pathogens and possible dysbiosis of microbiome during infancy \[[@pone.0221095.ref013]\]. In developing countries, it is known that in the absence of diarrhea, 15% of children under five years are infected with ETEC as asymptomatic carriers \[[@pone.0221095.ref014]\].

In the current EED cohort, we first examined the relationship of bacterial translocation marker along with gut and systemic inflammatory biomarkers in children with growth faltering \[[@pone.0221095.ref015]\]. The presence of IgA against bacterial flagellin and LPS was found to be associated with enteric inflammation and with subsequent decline in linear growth. In order to explore the contribution of enteropathogens in EED, we further characterized the association of enteropathogen burden with putative biomarkers and subsequent growth faltering at 18 months of age. We hypothesized that increased enteropathogen burden in the early period of life is associated with future decline in LAZ scores and corresponding changes in EED biomarker profiles. Identification of any single or a group of enteropathogens could provide early screening of children who are at risk of developing EED.

Material and methods {#sec002}
====================

Ethics statement {#sec003}
----------------

Institutional approval was granted by the Aga Khan University Ethical Review Committee (ERC\# 2446 Ped ERC 13) and the University of Virginia Institutional Review Board. All parents provided written informed consent for participation of their children in the study.

Study design and participants {#sec004}
-----------------------------

Subjects included in this analysis were part of a prospective community-based active surveillance birth cohort and were followed longitudinally for anthropometrics and biomarker measurements, response to Ready-to-Use-Therapeutic-Food (RUTF) and subsequent endoscopic/ histopathological examination in cases of inadequate growth response to RUTF \[[@pone.0221095.ref016], [@pone.0221095.ref017]\]. Additional descriptive characteristics of the study participants are shown in [S1 Table](#pone.0221095.s003){ref-type="supplementary-material"}.

Newborns (n = 272) were enrolled and assessed during routine surveillance of pregnant women of reproductive age (13--49 years) by community health workers (CHWs) \[[@pone.0221095.ref018]\]. Study inclusion criteria were: 1) newborns aged up to 14 days; 2) absence of any major congenital abnormalities and; 3) ability to obtain informed consent from parents or guardians. Infants of families planning to move out of the study area within 6 months of birth were excluded from the trial. Enrolled children were followed from birth (0 to 14 days) until 18 months of age with weekly home visits during the study period from October 2012 to November 2015 for diarrheal and acute respiratory infection episodes ([S1 Fig](#pone.0221095.s001){ref-type="supplementary-material"}). All families enrolled in the study were provided with cell phone contact information of key study physicians to enable direct and immediate contact in the case of any urgent medical need. Monthly measurements were recorded by trained Community Health Workers using standard techniques: child's weight using a digital infant balance with 20-g precision (TANITA 1584) and child's length using a rigid length board with a movable foot piece with 1 mm precision. Standardization of measurements was ensured through regular staff training and cross checks.

Biological specimen collection {#sec005}
------------------------------

Blood was obtained from enrolled children at 6 and 9 months of age. Samples were centrifuged in the field site research laboratory and plasma was removed within 2 h of blood collection. Samples were transported at 4°C from the field site at Matiari, Pakistan to the Aga Khan University Infectious Disease Research Lab (IDRL) under cold chain maintenance. Aliquots were stored at -80°C.

For collection of fecal samples, the mother/care-taker was instructed to use a diaper provided by the research staff that was lined with a thin plastic sheet to prevent absorption. Defecated samples were collected from the participant's homes. Using a clean spatula, the fecal samples were transferred to a clean container. The fecal samples were transported from the child's home to a peripheral laboratory in a 15 liter Coleman cooler with cold chain maintenance at 4°C. The samples were further aliquoted into small vials and were stored in the central laboratory IDRL at - 80ºC.

### Measurement of biomarkers {#sec006}

Peripheral blood samples were tested for flagellin and LPS-specific IgA and IgG concentrations measured by ELISA as previously reported \[[@pone.0221095.ref019]\]. Microtiter plates were coated with purified *E*. *coli* flagellin (100ng/well) or purified *E*. *coli* LPS (2 μg/well). Serum samples were diluted 1:200 and applied to the coated wells. After incubation and washing, the wells were incubated with anti-human IgA (KPL) or IgG (GE Healthcare) coupled to horseradish peroxidase. Quantification of total immunoglobulin was performed using the colorimetric peroxidase substrate tetramethylbenzidine (TMB) and read at 450 nm optical density (OD) on an ELISA plate reader. Data was reported as OD corrected by subtracting background levels, which were determined by reading in samples lacking serum. Commercial ELISA kits were used for the estimation of regenerating gene 1β (Reg 1b) (TechLab, Blacksburg, Virginia) in feces and serum. For intestinal inflammation, Myeloperoxidase (MPO) kit (Immunodiagnostic AG, Stubenwald-Allee, Bensheim) and Neopterin (NEO) (GenWay Biotech, San Diego, CA) were used for fecal samples as reported previously \[[@pone.0221095.ref020]\]. Biomarkers of systemic inflammation (C-reactive protein \[CRP\], alpha- 1-acid glycoprotein \[AGP\], and ferritin) were analyzed on the Hitachi 902 analyzer (Roche Diagnostics, Holliston, MA). All protocols were followed as per manufacturers' instruction. The final dilution for serum and fecal biomarkers was determined by selecting the most appropriate concentration of a biomarker falling in the linear range of standard curve. Reg 1b was performed in two dilutions of 1:40,000 and 1:100,000, NEO at the dilution of 1:250 and MPO at 1:500. All plates were read on the Biorad iMark (Hercules, CA) plate reader.

### TAC analysis of fecal samples {#sec007}

TaqMan Array card (TAC): The TaqMan low density array card or TAC allows molecular detection of multiple enteric pathogens using a customized detection platform based on a real time PCR detection system \[[@pone.0221095.ref021]\]. The enteric pathogen panel included viruses, bacteria and helminths. The TAC card was customized to detect microbial pathogens in the fecal samples collected at 6 months (n = 272) and 9 months (n = 271). This platform has been successfully used in our lab for multicenter studies such as GEMS and MAL-ED \[[@pone.0221095.ref022], [@pone.0221095.ref023]\]. Briefly, total nucleic acid (TNA) was extracted from approximately 180-220g of fecal samples using the bead beating method by adding 370mg of glass beads (Sigma, Aldrich, UK) followed by TNA extraction using QIAmp DNA Stool MiniKit (Qiagen,Germantown, MD). As per protocol, all samples were spiked with internal controls of PhHV (Phocine Herpes Virus) and MS2 (MS2 bacteriophage) as DNA and RNA targets respectively for validation of samples and to check the efficiency of extraction, reverse transcription and amplification steps. The TAC protocol was modified from the Next Generation Molecular Diagnostic project (Houpt Lab, University of Virginia, Charlottesville, USA). 100μl of TNA was eluted from the DNA extraction kit. Of this, 40 μl was mixed with 60μl of AgPath one step RT-PCR kit (Ambion, Applied Biosystem) and 100μl was loaded on a TAC card through microfluidic ports. The card was sealed and processed on ViiA7 (Applied Bio systems, Thermofisher, USA). A total of 8 samples were run in a single card along with extraction blank (consisting of nuclease free water with PhHV & MS2) and PCR blank (consisting of nuclease free water only). The samples were considered valid positive if target Ct value was less than 32, reference extraction blank was negative for target and internal control, and MS2 had Ct value less than 38.

These TAC cards were customized to detect 40 common enteropathogens including the following: Adenovirus, Aeromonas, *Ancylostoma*, *Ascaris*, Astrovirus, *Bacteroides fragilis*, *Campylobacter jejuni* and *Campylobacter coli*, *Clostridium difficile*, Cryptosporidium hominis and Cryptosporidium parvum, *Cyclospora*, *Encephalitozoon intestinalis*, *Entamoeba histolytica*, *Enterocytozoon bieneusi*, enteroaggregative *Escherichia coli* (EAEC), enteroinvasive *E*. *coli* (EIEC), enteropathogenic *E*. *coli* (EPEC), enterotoxigenic *E*. *coli* (ETEC), shigatoxigenic serotypes of *E*. *coli* (STEC), enterovirus, *Giardia*, *Helicobacter pylori*, *Isospora*, *Mycobacterium tuberculosis*, *Necator*, norovirus, rotavirus, *Salmonella*, sapovirus, *Shigella*, *Strongyloides*, *Trichuris*, and *Vibrio cholerae*.

Statistical analysis {#sec008}
--------------------

WHO Child Growth Standards (WHO Anthro, Geneva, Switzerland) \[[@pone.0221095.ref024]\] was used to calculate z-scores and assess growth both as continuous measures \[length-for-age z-score (LAZ), weight-for-age z-score (WAZ) and weight-for-height z-score (WHZ)\] and as categorized variables of stunting \[LAZ \< −2 SD (standard deviation), underweight as WAZ \< −2 SD and wasting as WHZ \< −2 SD\]. In accordance with WHO recommendations, we excluded outliers of LAZ (\<-6 or \>6), WHZ (\<-5 or \>5), and WAZ (\<-6 or \>5) \[[@pone.0221095.ref025]\].

Effect of specific enteropathogen infection on children's length over time was measured by using delta LAZ, a change in length-for-age (ΔLAZ = 18months-birth). The relationship between the change in z-scores (LAZ/WAZ/WHZ) and infection with specific pathogens at 6 and 9 months was modeled via simple linear regression to examine the unadjusted association of enteric infection (categorical variable, either yes or no for each pathogen) with the continuous outcome of change in LAZ score from birth to 18 months. Linear regression was used to further evaluate the association between ΔLAZ (dependent variable) with specific pathogens infection (independent variables), adjusting for antibiotics use: $$Model\ 1:\ \Delta LAZ = \beta_{0} + \beta_{1}\mspace{2mu} pathogen + \beta_{2}antibiotics + \varepsilon$$

Where β is the estimated regression coefficient, ε is the error term, "pathogen" (categorical variable) refers to whether or not each specific pathogen has infected a given child (a different term for each pathogen in the model), and "antibiotics" (categorical variable) refers to the use of antibiotic at least once during the period of 6 or 9 months as "Yes". Our approach was informed by a hypothesized conceptual causal diagram ([Fig 1](#pone.0221095.g001){ref-type="fig"}) for EED determinants. Correlations were calculated using Pearson correlation coefficient with associated 95% confidence between positive counts of pathogens (continuous variable) and ΔLAZ. Similar correlations were calculated between positive counts of pathogens (continuous variable) and our biomarkers of systemic inflammation (CRP, AGP, ferritin), enteric inflammation and intestinal regeneration (MPO, NEO, Reg 1b feces and serum), and bacterial translocation (anti-flic and anti-LPS IgA and IgG).

![Hypothesized causal pathways for environmental enteric dysfunction (EED).\
Analyses included factors highlighted in blue in order to model the relationship between fecal enteropathogens and markers of bacterial translocation, inflammatory biomarkers with growth faltering in association with EED.](pone.0221095.g001){#pone.0221095.g001}

Biomarkers found to be significantly correlated with increasing pathogen counts were taken as part of a sub-analysis in which we used linear regression models at 6 months (anti-flic IgA, MPO, Reg 1b feces and serum) and 9 months (CRP, AGP, Reg 1b feces and serum) with each biomarker as the dependent variable and infection with specific pathogens as independent variables (categorical variable) with antibiotic use included as a covariate: $$Model\ 2:\ Biomarker = \beta_{0} + \beta_{1}\mspace{2mu} pathogen_{1} + \beta_{2}pathogen_{2} + \ldots + \beta_{k}pathogen_{k} + \beta_{k + 1}antibiotics + \varepsilon$$

Where β is the estimated regression coefficient, ε is the error term, "pathogen~k~" (categorical variable) refers to whether or not each specific pathogen has infected a given child (a different term for each pathogen in the model), and "antibiotics" (categorical variable) refers to the use of antibiotics at 6 and 9 months. This multivariable analysis was performed for each biomarker. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).

Results {#sec009}
=======

Impact of enteropathogens burden on LAZ {#sec010}
---------------------------------------

[Table 1](#pone.0221095.t001){ref-type="table"} shows the proportions of children infected with different pathogen subtypes and their respective mean LAZ scores. In each category of enteropathogen that included bacteria, viruses and protozoa, no difference was found in the mean LAZ score in children with or without particular infection. This trend was similar at both 6 and 9 months.

10.1371/journal.pone.0221095.t001

###### Characteristics of the Pakistani cohort at 6 months (N = 272) and 9 months (N = 271) with regards to pathogen infection and length-for-age Z (LAZ) scores.

![](pone.0221095.t001){#pone.0221095.t001g}

                  Enteropathogens at 6 months   Enteropathogens at 9 months                                                                                                                                                                                                       
  --------------- ----------------------------- ----------------------------- ------------- -------------- -------------- -------------- ------------- ------------- ------------- ------------- ------------- ------------- ----------- ---------- ------ ------------ --------- ------
  N (%)           247(90.1)                     27(9.9)                       0.93          137(50.0)      137 (50.0)     0.70           249 (92.9)    25 (7.1)      0.099         256(93.8)     17(6.2)       0.098         194(71.1)   79(28.9)   0.42   253 (92.7)   20(7.3)   0.35
  LAZ Mean (SD)   -2.73 (1.08)                  -2.70(1.67)                   -2.75(1.15)   -2.70 (1.14)   -2.69 (1.16)   -3.09 (0.90)   -2.76(1.15)   -2.28(0.97)   -2.77(1.18)   -2.64(1.05)   -2.75(1.16)   -2.50(0.87)                                                        

Notes: "Yes" = infection with 1 or more pathogens of the specified category. "No" = no infections of the specified category. LAZ18 = length-for-age Z score at the 18th months of life. None of the differences in LAZ score between children infected or not infected with pathogens of a given category were significant. p^¥^ (p-value) refers to the difference between mean LAZ scores at 18 months of age in the groups positive and negative for enteropathogens at 6 or 9 months.

Association of enteropathogen counts with ΔLAZ score and inflammatory biomarkers {#sec011}
--------------------------------------------------------------------------------

Overall, the frequency of bacterial infection was found to be similar in the samples collected at 6 and 9 months with the exception of Campylobacter and Cryptosporidium. Among viral and protozoal pathogens, Adenovirus, Sapovirus, Giardia and Cryptosporidium frequencies were higher at 9 months compared to 6 months ([S2 Fig](#pone.0221095.s002){ref-type="supplementary-material"})

[Table 2](#pone.0221095.t002){ref-type="table"} shows correlation coefficients between growth and enteropathogen burden. There was a significant negative correlation between enteropathogen counts of all subtypes at 6 months and ΔLAZ (18 months-birth). This effect was no longer significant at 9 months. We further analyzed positive counts of enteropathogen with putative EED biomarkers. Presence of enteropathogen (all positive for bacteria, virus, protozoa) correlated with serum flagellin (flic) IgA, fecal Reg 1b and serum Reg 1b. Infection with bacteria correlated with MPO, protozoa with CRP, AGP and Ferritin, while viral infection with CRP.

10.1371/journal.pone.0221095.t002

###### Correlation coefficient matrix of biomarkers^¥^ and the change in Z scores for length over the first 18 months of life with the number of enteropathogens infecting children at 6 and 9 months.

![](pone.0221095.t002){#pone.0221095.t002g}

                                                                                            Enteropathogens at 6 months                     Enteropathogens at 9 months                                                                                                                                                                                                                                                  
  ----------------------------------------- ----------------------------------------------- ----------------------------------------------- --------------------------------------------- --------------------------------------------- -------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- --------------------------------------------
  **Growth**                                ΔLAZ                                            -0.2[1\*](#t002fn005){ref-type="table-fn"}      -0.12                                         -0.15[\*](#t002fn005){ref-type="table-fn"}    -0.15[\*](#t002fn005){ref-type="table-fn"}   -0.062                                      -0.017                                      -0.036                                      -0.075
  **Bacterial Translocation**               Anti-LPS IgA, OD                                0.098                                           0.04                                          0.077                                         0.091                                        -0.0078                                     -0.046                                      -0.013                                      0.067
  Anti-LPS IgG, OD                          0.036                                           0.09                                            -0.049                                        -0.0095                                       -0.030                                       0.011                                       -0.041                                      -0.043                                      
  Anti-flic IgA, OD                         0.19[\*](#t002fn005){ref-type="table-fn"}       -0.0017                                         0.22[\*\*](#t002fn004){ref-type="table-fn"}   0.23[\*\*](#t002fn004){ref-type="table-fn"}   0.0026                                       -0.055                                      0.013                                       0.078                                       
  Anti-flic IgG, OD                         0.039                                           0.051                                           0.012                                         -0.0053                                       -0.052                                       -0.056                                      -0.048                                      0.019                                       
  **Systemic Inflammation**                 CRP, mg/L                                       0.085                                           0.11                                          0.0072                                        0.011                                        0.066                                       0.075                                       0.16[\*](#t002fn003){ref-type="table-fn"}   -0.13[\*](#t002fn003){ref-type="table-fn"}
  AGP, mg/dL                                0.018                                           0.040                                           0.016                                         -0.039                                        0.088                                        0.029                                       0.18[\*](#t002fn003){ref-type="table-fn"}   -0.030                                      
  Ferritin, ng/mL                           -0.093                                          -0.11                                           0.069                                         -0.10                                         0.061                                        -0.036                                      0.19[\*](#t002fn003){ref-type="table-fn"}   0.0066                                      
  **Enteric inflammation & regeneration**   MPO, ng/mL                                      0.083                                           0.15[\*](#t002fn003){ref-type="table-fn"}     0.024                                         -0.076                                       0.045                                       0.020                                       0.042                                       0.028
  NEO, nmol/L                               0.024                                           -0.015                                          0.013                                         0.067                                         -0.075                                       -0.057                                      -0.099                                      0.018                                       
  Reg 1b Serum, ng/mL                       0.26[\*\*\*](#t002fn003){ref-type="table-fn"}   0.28[\*\*\*](#t002fn003){ref-type="table-fn"}   0.12[\*](#t002fn003){ref-type="table-fn"}     0.035                                         0.15[\*](#t002fn003){ref-type="table-fn"}    0.16[\*](#t002fn003){ref-type="table-fn"}   0.028                                       0.055                                       
  Reg 1b fecal, μg/g                        0.16[\*](#t002fn003){ref-type="table-fn"}       0.16[\*](#t002fn003){ref-type="table-fn"}       0.10                                          0.015                                         0.16[\*](#t002fn003){ref-type="table-fn"}    0.11                                        0.10                                        0.082                                       

The following were studied as continuous variables: Counts of all positive pathogens, counts of positive bacteria, counts of positive protozoa, counts of positive viruses and all biomarker concentrations.

Note: Values are Pearson correlation coefficients.

\*\*\*p-value\<0.0001

\*\*p-value\<0.001

\*p-value\<0.05.

Abbreviations: Flagellin = flic; Immunoglobulin = Ig; Lipopolysaccharide = LPS; alpha glycoprotein = AGP; C-reactive protein = CRP; Myeloperoxidase = MPO; Neopterin = NEO; regenerating gene 1 beta = Reg 1b, change in length-for-age Z scores over the first 18 months of life = ΔLAZ. ¥Biomarkers measured were indicative of systemic inflammation, bacterial translocation, enteric inflammation, or intestinal regeneration (left column indicates which biomarkers fall into each category).

Infection with enteropathogens is associated with change in LAZ score {#sec012}
---------------------------------------------------------------------

[Table 3](#pone.0221095.t003){ref-type="table"} shows the association of ΔLAZ^(18month-birth)^ with specific enteropathogen at 6 and 9 months of age. We found a nominally significant decline in LAZ with the positivity of Astrovirus, *Campylobacter*, Cryptosporidium and *Giardia* at 6 months (nominal p-value \< 0.05). The effects of these enteropathogens on ΔLAZ became insignificant at threshold of 0.05 after the adjustment for false discovery rate (FDR). Nevertheless, *Campylobacter*, Cryptosporidium and *Giardia* were marginally associated with ΔLAZ at FDR threshold of 0.1. There was minimal or no change in delta LAZ for the given pathogens at 9 months compared to those at 6 months after FDR adjustment, even if Norovirus at 9 months was significantly associated with ΔLAZ at nominal significance level.

10.1371/journal.pone.0221095.t003

###### The association of selected enteropathogens \[at 6 (n = 272) and 9 (n = 271) months\] with changes in LAZ scores over the first 18 months of life.

![](pone.0221095.t003){#pone.0221095.t003g}

                                Enteropathogens at 6 months   Enteropathogens at 9 months                                               
  ----------------------------- ----------------------------- ----------------------------- ----------- ------- -------- ------ ------- -------
  Adenovirus 40/41              -0.05                         0.25                          0.856       0.856   -0.11    0.19   0.599   0.982
  Astrovirus                    -0.38                         0.19                          **0.046**   0.116   0.07     0.21   0.725   0.982
  *Bacteroides fragilis*        0.33                          0.21                          0.121       0.192   -0.08    0.18   0.681   0.982
  *Campylobacter jejuni/coli*   -0.36                         0.16                          **0.025**   0.091   -0.15    0.15   0.294   0.874
  *Campy_pan*                   -0.36                         0.15                          **0.014**   0.090   -0.10    0.14   0.455   0.982
  Cryptosporidium               -0.45                         0.20                          **0.028**   0.091   -0.004   0.15   0.982   0.982
  *Cyclospora*                  0.26                          0.66                          0.688       0.688   0.44     0.36   0.228   0.874
  EAEC                          -0.21                         0.15                          0.180       0.225   -0.14    0.17   0.420   0.982
  EIEC *Shigella*               -0.41                         0.31                          0.191       0.225   -0.03    0.24   0.902   0.982
  EPEC                          -0.004                        0.14                          0.979       0.979   0.003    0.14   0.982   0.982
  ETEC_LT                       -0.03                         0.16                          0.842       0.842   0.23     0.16   0.146   0.788
  ETEC \_STh                    -0.54                         -1.6                          0.107       0.192   0.06     0.27   0.820   0.982
  ETEC_STp                      -0.05                         0.27                          0.846       0.846   -0.37    0.27   0.158   0.788
  *Enterocytozoon bieneusi*     0.65                          0.33                          0.054       0.116   -0.013   0.21   0.951   0.982
  Enterovirus                   -0.17                         0.16                          0.278       0.301   -0.11    0.16   0.517   0.982
  *Giardia*                     -0.57                         0.23                          0.013       0.090   -0.36    0.19   0.055   0.546
  Norovirus GI&II               -0.22                         0.15                          0.133       0.192   -0.29    0.15   0.050   0.546
  Rotavirus                     0.21                          0.26                          0.426       0.426   -0.13    0.33   0.702   0.982
  STEC Stx1 stx2                0.30                          0.44                          0.494       0.494   0.10     0.32   0.748   0.982
  Sapovirus                     -0.14                         0.25                          0.565       0.565   -0.16    0.15   0.306   0.874

Notes: This regression model has been described in the Methods section as Model 1: ΔLAZ (18mo-birth) = β~0~ + β~1~ pathogen + β~2~ antibiotics + ε. The β~1~ is the estimated effect of each pathogen obtained from a linear regression model using ΔLAZ score as the dependent variable (continuous) and the presence of each pathogen (categorical) as the independent variable, adjusting for the antibiotic use (categorical variable) at 6 or 9 months. ΔLAZ refers to the change in length-for-age Z scores over the first 18 months of life. Nominal p-values were directly estimated from the regression, while FDR-adjusted p-values were calculated using Proc MULTTEST in SAS to account for multiple comparisons.

Infection with specific enteropathogens is associated with an increase in inflammatory biomarkers {#sec013}
-------------------------------------------------------------------------------------------------

In order to analyze the effect of enteropathogen infection on inflammatory biomarkers, we selected biomarkers based on their significant correlation with increasing enteropathogen count ([Table 2](#pone.0221095.t002){ref-type="table"}). The significant associations at 6 months included anti-flic IgA with astrovirus infection, anti-flic IgA with STEC (stx1, stx2) infection, MPO with *Campylobacter* infection, serum Reg 1b with ETEC ST infection, fecal Reg1 β with *Giardia* ([Table 4](#pone.0221095.t004){ref-type="table"}). At 9 months, only serum Reg 1b reported significant correlation with *Campylobacter* infection ([S2 Table](#pone.0221095.s004){ref-type="supplementary-material"}).

10.1371/journal.pone.0221095.t004

###### The association of select enteropathogens at 6 months (n = 272) with levels of specific biomarkers¥ at 6 months.
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  Enteropathogens          Biomarkers at 6 months                                                                                                                                                                                                                                     
  ------------------------ ------------------------ ------- ------------------------------------------------- ------------ ----------- ------------------------------------------------- --------- --------- --------------------------------------------------- ---------- --------- -------------------------------------------------
  *Aeromonas*              -0.037                   0.083   0.6540                                            -3939.221    10181.900   0.6992                                            -42.499   68.685    0.5366                                              -25.243    107.376   0.8143
  *Bacteroides fragilis*   0.046                    0.032   0.1521                                            -1370.069    3815.262    0.7198                                            48.266    26.182    0.0664                                              -20.334    40.886    0.6194
  *C*. *difficile*         0.162                    0.095   0.0888                                            15637.007    11575.970   0.1779                                            39.208    78.085    0.6160                                              -138.291   122.126   0.2586
  *Campylobacter*          -0.038                   0.021   0.0750                                            7751.217     2608.554    **0.0032**[\*](#t004fn004){ref-type="table-fn"}   5.972     17.717    0.7363                                              47.283     27.842    0.0907
  EAEC                     0.010                    0.023   0.6525                                            3825.984     2765.798    0.1678                                            -1.241    18.999    0.9480                                              -32.145    29.305    0.2737
  EIEC *Shigella*          0.000                    0.048   0.9943                                            1174.943     5827.794    0.8404                                            66.294    39.374    0.0935                                              105.623    61.463    0.0869
  EPEC                     0.026                    0.022   0.2287                                            -3996.395    2666.754    0.1352                                            51.733    18.301    **0.0051**[\*](#t004fn004){ref-type="table-fn"}     7.466      28.322    0.7923
  ETEC LT                  0.061                    0.025   0.0140                                            7089.216     3015.043    **0.0195**[\*](#t004fn004){ref-type="table-fn"}   34.956    20.396    0.0878                                              30.101     31.852    0.3456
  ETEC ST                  -0.107                   0.050   **0.0343**[\*](#t004fn004){ref-type="table-fn"}   -1404.007    6136.554    0.8192                                            240.406   41.390    **\<0.0001**[\*](#t004fn004){ref-type="table-fn"}   54.556     64.725    0.4001
  *H*. *pylori*            -0.096                   0.164   0.5576                                            -22212.603   20006.355   0.2679                                            -64.679   134.924   0.6321                                              -91.621    211.046   0.6646
  STEC stx1 & stx2         -0.201                   0.064   **0.0020**[\*](#t004fn004){ref-type="table-fn"}   -5795.417    7852.027    0.4611                                            -72.567   52.976    0.1720                                              48.500     82.830    0.5587
  Cryptosporidium          0.017                    0.031   0.5801                                            143.496      3779.297    0.9697                                            42.626    28.721    0.1390                                              6.316      38.985    0.8714
  *Cyclospora*             0.009                    0.101   0.9301                                            -12792.821   12445.159   0.3049                                            58.113    91.815    0.5273                                              -175.403   128.178   0.1724
  *E*. *bieneusi*          0.089                    0.049   0.0673                                            -7183.708    5992.814    0.2317                                            12.197    44.231    0.7830                                              -41.989    64.349    0.5146
  *Giardia*                0.054                    0.021   **0.0091**[\*](#t004fn004){ref-type="table-fn"}   3249.669     2533.286    0.2007                                            11.925    18.871    0.5280                                              72.198     26.394    **0.0067**[\*](#t004fn004){ref-type="table-fn"}
  *Trichuris*              0.001                    0.165   0.9960                                            7909.737     20352.996   0.6979                                            -25.837   150.156   0.8635                                              -95.863    209.633   0.6478
  Adenovirus 40/41         0.052                    0.025   **0.0399**[\*](#t004fn004){ref-type="table-fn"}   -5678.013    3073.041    0.0658                                            45.478    23.272    0.0518                                              6.561      33.448    0.8446
  Astrovirus               0.093                    0.028   **0.0008**[\*](#t004fn004){ref-type="table-fn"}   6102.398     3371.487    0.0714                                            13.766    25.397    0.5883                                              21.750     36.408    0.5508
  Enterovirus              0.029                    0.023   0.2015                                            3258.000     2795.368    0.2449                                            -47.315   21.170    **0.0263**[\*](#t004fn004){ref-type="table-fn"}     -20.881    30.004    0.4871
  Norovirus GI, GII        0.036                    0.021   0.0902                                            -1707.927    2582.729    0.5090                                            21.473    19.581    0.2738                                              31.404     27.746    0.2588
  Rotavirus                0.035                    0.037   0.3492                                            -5967.456    4572.710    0.1930                                            6.533     34.087    0.8482                                              -36.507    50.040    0.4663
  Sapovirus                0.012                    0.037   0.7378                                            -8799.921    4399.301    **0.0465**[\*](#t004fn004){ref-type="table-fn"}   -34.222   32.823    0.2981                                              6.039      46.964    0.8978

Note: This regression model has been described in the methods section as Model 2: Biomarker = β~0~ + β~1~ pathogen~1~ + β~2~ pathogen~2~ + ... + β~k~pathogen~k~ + β~k+1~ antibiotics + ε. β~k~ is estimated effects of each pathogen obtained via a multiple linear regression model using the levels of biomarkers at 6 months as the dependent variable (continuous) and the presence of each pathogen (categorical) as multiple independent variables. Antibiotic use (categorical variable) was included in the model as a covariate.

\*\*\*p-value\<0.0001

\*\*p-value\<0.001

\*p-value\<0.05

Abbreviations: Flagellin = flic; Immunoglobulin = Ig; alpha glycoprotein = AGP; C-reactive protein = CRP; Myeloperoxidase = MPO; regenerating gene 1 beta = Reg1b

¥Biomarkers were indicative of systemic inflammation (CRP, AGP), bacterial translocation (anti-flic IgA), enteric inflammation (MPO), and intestinal regeneration (Reg1b). The specific biomarkers included in this analysis were chosen because they significantly correlated with increasing pathogen counts at either 6 or 9 months

Discussion {#sec014}
==========

In the context of EED, the present study highlights the association between enteropathogens and linear growth--an association hypothesized to be mediated through enteric and systemic inflammatory pathway \[[@pone.0221095.ref015]\]. The key findings of our study are: a) the presence of at least one enteropathogen in fecal samples at 6 and 9 months of age ([Table 1](#pone.0221095.t001){ref-type="table"}) (at least one bacteria, one protozoa and one virus); b) a negative correlation of delta LAZ with observed pathogen at 6 months ([Table 2](#pone.0221095.t002){ref-type="table"}); and c) an association of specific enteropathogens with positive or negative changes in beta estimates of EED biomarkers as outcome variable.

Overall we found that subclinical infection with entropathogen was marginally associated with linear growth. The presence of similar pathogens such as Giardia, Campylobacter and Cryptosporidium also showed substantial negative association in MAL-ED cohort \[[@pone.0221095.ref026]\].

In our study, we found that *Campylobacter* infection at 6 months of age had a negative effect on future LAZ at nominal significance level and the effect became marginally after FDR adjustment ([Table 3](#pone.0221095.t003){ref-type="table"}). *Campylobacter* infection has been linked to inflammation and disruption of the gut barrier functions \[[@pone.0221095.ref027]\], and with reduced weight gain in developing nations \[[@pone.0221095.ref028]\]. Additionally, the GEMS study, which focused on characterizing the burden of diarrheal disease in Asia and Africa, identified *Campylobacter* as an important contributor to the diarrheal disease burden with regional importance in Pakistan, Bangladesh and India \[[@pone.0221095.ref029]\]. Since the GEMS study focused on diarrheal episodes, it is interesting to observe an association of *Campylobacter* with asymptomatic children with linear growth faltering. We also found that *Campylobacter* infection was associated with an increased expression of fecal MPO and to some extent increase in Reg1b, a marker of enterocyte regeneration. Although both MPO and NEO have previously shown to be highly associated with intestinal inflammation as well as growth failure in children \[[@pone.0221095.ref020], [@pone.0221095.ref030], [@pone.0221095.ref031]\]. Our study did not identify any correlation between the presence of *Campylobacter* with NEO per se. In light of prior research, it is clear that *Campylobacter* is a pathogen of emerging importance and is involved in the causal pathway of environmental enteropathy in developing countries.

The presence of Cryptosporidium and *Giardia* at 6 months showed negative decline in LAZ (range -0.3 to -0.5) in the first 18 months of life, which was also supported by other malnourished cohorts \[[@pone.0221095.ref032]\] \[[@pone.0221095.ref033]\]. Early infection of children with Cryptosporidium and *Giardia* at 6 months of age is associated with linear growth faltering. The presence of the above pathogens was associated with a significant decline in LAZ (range -0.3 to -0.5) in the first 18 months of life \[[@pone.0221095.ref011], [@pone.0221095.ref034]\]. In the GEMS study, Cryptosporidium infection was ranked among top three pathogens associated with linear growth in children with less-severe diarrhea (LSD) and moderate-to-severe diarrhea (MSD) as per GEMS definition \[[@pone.0221095.ref011], [@pone.0221095.ref034]\]. Additionally, *Giardia* infection has also been associated with intestinal permeability, malabsorption \[[@pone.0221095.ref033]\], and poor linear growth, as hallmark features of EED \[[@pone.0221095.ref033], [@pone.0221095.ref035]\]. Furthermore, Berkman et al studied the effect of *Giardia* infection on malnutrition and cognitive development in older children, as an important outcome of EED \[[@pone.0221095.ref036]\] \[[@pone.0221095.ref037]\].

Among etiologies of diarrheal infection, Norovirus has been identified as an important enteropathogen of malnutrition and growth faltering in the Mal-ED and GEMS studies \[[@pone.0221095.ref029], [@pone.0221095.ref038]\]. Association of Norovirus and malnutrition is well established in murine model \[[@pone.0221095.ref039]\], which may involve in modulation of tight junctions. In asymptomatic children with non-diarrheal stools, we did not find any significance of Norovirus on growth decline.

Increased pathogen count at 6 months also correlated with increase in anti-flic IgA levels, an activation signal of innate immune response initiated by recognition of PAMPS (bacterial flagellin) by Toll-like receptor 5 (TLR5), which activates downstream signaling pathway of NF-kB regulated pro-inflammatory proteins. Bacterial flagellin is thought to be involved in mucosal damage by targeting the basolateral surface of intestinal cells. \[[@pone.0221095.ref040], [@pone.0221095.ref041]\]. In our cohort, we also found an association of antibodies against Anti-flic IgA with biomarkers of intestinal inflammation and regeneration (MPO and Reg1b) \[[@pone.0221095.ref015]\]. Anti-flic IgA antibodies are therefore considered a marker of translocation of flagellin-producing bacteria in blood \[[@pone.0221095.ref042]\].

Reg1b is a marker of enterocyte regeneration \[[@pone.0221095.ref043]\], which is associated with presence of enterotoxigenic *E*. *coli* (ETEC) and *Campylobacter* infections at 6 and 9 months of age. Reg 1b is a predictor of childhood stunting in Bangladeshi cohort \[[@pone.0221095.ref044]\]. Reg1β did not show a direct relationship with linear growth faltering previously shown in this cohort \[[@pone.0221095.ref016]\]

We found that biomarkers of systemic inflammation, CRP, AGP and Ferritin, were not significantly associated with overall burden of pathogens. On stratification, only protozoal infection at 9 months was moderately correlated with inflammatory markers, which indicates the process of cellular damage and activation of immune mechanism. Such an increase in CRP has been reported in travelers in tropics with protozoal infections \[[@pone.0221095.ref045]\]. In the acute phase of bacterial diarrhea in Egyptian children, CRP was identified as marker of acute inflammation along with Trem-1 and Procalcitonin \[[@pone.0221095.ref046]\]. The lack of CRP elevation in our study could reflect low frequency of diarrhea in our children and indicates that they had probably passed the acute phase of infection. An early rise in CRP and AGP have been associated with stunting in Zimbabwean infants and, as recently reported, with future stunting in this Pakistani cohort \[[@pone.0221095.ref018], [@pone.0221095.ref047]\]. Furthermore, a recent South Indian study evaluated asymptomatic carriage of enteropathogens in children from two communities to study the effect of the environment on pathogen burden and corresponding changes in inflammatory biomarkers \[[@pone.0221095.ref048]\]. In comparison to this study, our study had a longitudinal study design for both biological sample collection and anthropometric measurements. We also analyzed a larger panel of pathogens and wider array of systemic/gut inflammatory biomarkers. Our analyses also focused on association of enteropathogen with changes in LAZ and varying levels of biomarkers.

Strengths of our study include: a) longitudinal follow-up with prospective repeated measures of growth; b) use of a highly sensitive platform that has shown superior sensitivity in the detection of enteropathogens as already been utilized in the MAL-ED \[[@pone.0221095.ref023]\] and GEMS cohorts \[[@pone.0221095.ref011]\], and c) co-existence of enteropathogens and EED biomarkers spanning gut-specific, systemic, and mucosal inflammatory responses. Our study is limited with a) censoring of data at 18 months of age, thus limiting follow-up beyond 18 months to be able to ascertain the persistence of infection and outcome on long term growth and cognition; b) we evaluated growth faltering as changes in the linear slope of z scores, and thus were limited in using growth faltering at the first 18 months of life as a clinical proxy of EED; and lastly c) we were unable to collect dietary information in this cohort to correlate these important findings and d) multiple comparison of pathogens and biomarker data in regression model lost some of the significance after correction for FDR. Also, the growth modelling did not account for early and later stunting in this cohort.

Conclusion {#sec015}
==========

In conclusion, childhood infection with increasing numbers of pathogens is associated with an increase in biomarkers of inflammation and intestinal permeability with a decrease in linear growth. Moreover, specific pathogens, such as *Campylobacter*, Cryptosporidium *and Giardia* seem to play a key role in such associations with growth and increase in inflammatory biomarkers which may be involved in the process of EED. With the advent of a combination vaccine against *Shigella* and enterotoxigenic *E*. *coli*, prevention of enteric infections may reduce the risk of enteric infections that seem to play a critical role in the pathogenesis of EED.

Supporting information {#sec016}
======================

###### Cumulative Z scores with comorbidity data up to 18 months of age.

Descriptive data regarding the length-for-age (LAZ), weight-for-age (WAZ), and weight-for-length (WHZ) Z scores for the Pakistani cohort over the course of the first 18 months of life (scatterplot and left y-axis). Also included are data regarding the mean number of days in each month that children reported diarrhea or acute respiratory infection (ARI), defined as the presence of a cough and/or runny nose (bars, right y-axis).
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Click here for additional data file.

###### Bar graph representing frequencies of pathogens detected by Array card.

Comparison of the frequencies of bacterial (A), viral (B) and protozoal (C) enteropathogens detected in the cohort A (6 months) and cohort B (9 months).
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Click here for additional data file.

###### Additional descriptive statistics for the children in the analysis.
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Click here for additional data file.

###### The association of select enteropathogens at 9 months (n = 271) with levels of specific biomarkers¥ at 9 months.

Note: This regression model has been described in the methods section as Model 2: Biomarker = β0 + β1 pathogen1 + β2pathogen2 + ... + βnpathogenn + βn+1antibiotics + ε. The β estimates for each pathogen were obtained via a multiple linear regression model using the levels of biomarkers over the first 18 months of life as the dependent variable (continuous) and the presence of each pathogen (categorical) as multiple independent variables. Antibiotic use (categorical variable) was included in the model as a covariate. \*\*\*p-value\<0.0001; \*\*p-value\<0.001; \*p-value\<0.05 Abbreviations: Flagellin = flic; Immunoglobulin = Ig; alpha glycoprotein = AGP; C-reactive protein = CRP; Myeloperoxidase = MPO; regenerating gene 1 beta = Reg 1b

¥Biomarkers were indicative of systemic inflammation (CRP, AGP), bacterial translocation (anti-flic IgA), enteric inflammation (MPO), and intestinal regeneration (Reg 1b). The specific biomarkers included in this analysis were chosen because they significantly correlated with increasing pathogen counts at either 6 or 9 months.

(DOCX)

###### 

Click here for additional data file.
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